Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 2015

View Archived Issues

MI-mAbs immunotechnology center launched in France

EMD Serono amends agreement with Opexa to support Tcelna development

Radius Health acquires license to develop and market RAD-1901 in Japan

Spry-2 shows potential as a prognostic biomarker in ovarian cancer

MazF-modified T cells are safe and persistant in aviremic HIV patients

Novel HPV vaccine increases seroconversion levels after each vaccination

TWi Biotechnology receives rare disease drug designation for AC-203 in Taiwan

MedImmune and Joslin Diabetes Center form new collaboration for metabolic disease research

LDC receives grants to develop new drug candidates

Illumina and Merck Serono collaborate to develop universal NGS-based oncology diagnostic

Novel crossmab antibody shows efficacy in neovascular disease of the eye

Madison Vaccines confirms program expansions for prostate cancer vaccines

Stratatech reports topline results from proof-of-concept study of StrataGraft skin tissue

Merrimack uses RNAscope to select patients for phase II NSCLC trial of MM-121

Halozyme Therapeutics selects first product candidate under Janssen collaboration

Boehringer Ingelheim divulges BRD4/HUNK1 inhibitors

FDA accepts for review Spectrum's Captisol-Enabled Melphalan NDA

Multi-kinase inhibitor shows potential for AMD

Ocular Therapeutix reports phase III results for dexamethasone punctal plug

FDA approves Unituxin for pediatric patients with high-risk neuroblastoma

Merck & Co.'s pembrolizumab is first drug accepted in U.K. Early Access to Medicines Scheme

Ophthotech achieves new milestone under Fovista agreement with Novartis

Interim analysis completed for phase III trial of AM-101 in post-acute tinnitus

Merck & Co. patents PAR-1 antagonists

Allergan describes S1P1 receptor modulators

Roche and Genetech disclose MAP3K14 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...